Immuneering Corp (IMRX): Cash & Equivalents
$128.65M
As of 2025-12-31
$41.32M
As of 2026-06-30
+21.0%
3-year compound annual growth
+28.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $128.65M | +255.9% | 2026-03-06, Balance as of period end |
| 2024-12-31 | $36.14M | -39.2% | 2026-03-06, Balance as of period end |
| 2023-12-31 | $59.41M | -18.2% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $72.64M | -3.0% | 2024-03-01, Balance as of period end |
| 2021-12-31 | $74.89M | +101.9% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $37.09M | n/a | 2022-03-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Immuneering Corp (IMRX) | 2025-12-31 | $128.65M | +255.9% |
| Oramed Pharmaceuticals Inc. (ORMP) | 2025-12-31 | $45.95M | -15.6% |
| Design Therapeutics, Inc. (DSGN) | 2025-12-31 | $16.86M | -25.3% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $53.83M | -38.1% |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $45.45M | -36.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $44.06M | +171.1% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.27M | -2.3% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $213.19M | +513.2% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $78.44M | +235.8% |
Compare IMRX, ORMP, DSGN, EOLS side by side · Screen every company in Pharmaceutical Preparations ↗